Haemoglobin mass and running time trial performance after recombinant human erythropoietin administration in trained men

Durussel, J., Daskalaki, E., Anderson, M., Chatterji, T., Wondimu, D.H., Padmanabhan, N., Patel, R.K., McClure, J.D. and Pitsiladis, Y.P. (2013) Haemoglobin mass and running time trial performance after recombinant human erythropoietin administration in trained men. PLoS ONE, 8(2), e56151. (doi: 10.1371/journal.pone.0056151) (PMID:23418527) (PMCID:PMC3571963)

[img]
Preview
Text
76024.pdf - Published Version
Available under License Creative Commons Attribution.

654kB

Abstract

<p>Recombinant human erythropoietin (rHuEpo) increases haemoglobin mass (Hbmass) and maximal oxygen uptake (v˙ O2 max).</p> <p>Purpose: This study defined the time course of changes in Hbmass, v˙ O2 max as well as running time trial performance following 4 weeks of rHuEpo administration to determine whether the laboratory observations would translate into actual improvements in running performance in the field.</p> <p>Methods: 19 trained men received rHuEpo injections of 50 IUNkg21 body mass every two days for 4 weeks. Hbmass was determined weekly using the optimized carbon monoxide rebreathing method until 4 weeks after administration. v˙ O2 max and 3,000 m time trial performance were measured pre, post administration and at the end of the study.</p> <p>Results: Relative to baseline, running performance significantly improved by ,6% after administration (10:3061:07 min:sec vs. 11:0861:15 min:sec, p,0.001) and remained significantly enhanced by ,3% 4 weeks after administration (10:4661:13 min:sec, p,0.001), while v˙ O2 max was also significantly increased post administration (60.765.8 mLNmin21Nkg21 vs. 56.066.2 mLNmin21Nkg21, p,0.001) and remained significantly increased 4 weeks after rHuEpo (58.065.6 mLNmin21Nkg21, p = 0.021). Hbmass was significantly increased at the end of administration compared to baseline (15.261.5 gNkg21 vs. 12.761.2 gNkg21, p,0.001). The rate of decrease in Hbmass toward baseline values post rHuEpo was similar to that of the increase during administration (20.53 gNkg21Nwk21, 95% confidence interval (CI) (20.68, 20.38) vs. 0.54 gNkg21Nwk21, CI (0.46, 0.63)) but Hbmass was still significantly elevated 4 weeks after administration compared to baseline (13.761.1 gNkg21, p<0.001).</p> <p>Conclusion: Running performance was improved following 4 weeks of rHuEpo and remained elevated 4 weeks after administration compared to baseline. These field performance effects coincided with rHuEpo-induced elevated v˙ O2 max and Hbmass.</p>

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Patel, Dr Rajan and Daskalaki, Miss Evangelica and Pitsiladis, Dr Yannis and Padmanabhan, Dr Neal and Wondimu, Mr Diresibachew and McClure, Dr John
Authors: Durussel, J., Daskalaki, E., Anderson, M., Chatterji, T., Wondimu, D.H., Padmanabhan, N., Patel, R.K., McClure, J.D., and Pitsiladis, Y.P.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:PLoS ONE
Publisher:Public Library of Science
ISSN:1932-6203
Published Online:13 February 2013
Copyright Holders:Copyright © 2013 The Authors
First Published:First published PLoS ONE 8(2):e56151
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record